Δημοσίευση

Lipoprotein a: where are we now?

ΤίτλοςLipoprotein a: where are we now?
Publication TypeJournal Article
Year of Publication2009
AuthorsTziomalos, K., Athyros V. G., Wierzbicki A. S., & Mikhailidis D. P.
JournalCurr Opin Cardiol
Volume24
Issue4
Pagination351-7
Date Published2009 Jul
ISSN1531-7080
Λέξεις κλειδιάAnticholesteremic Agents, Coronary Artery Disease, Disease Progression, Fibrinolysis, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Inflammation, Lipoprotein(a), Peripheral Vascular Diseases, Risk Assessment, Risk Factors, Stroke
Abstract

PURPOSE OF REVIEW: To provide an update of the literature describing the link between lipoprotein a and vascular disease.RECENT FINDINGS: There is evidence that elevated plasma lipoprotein a levels are associated with coronary heart disease, stroke and other manifestations of atherosclerosis. Several mechanisms may be implicated, including proinflammatory actions and impaired fibrinolysis.SUMMARY: Lipoprotein a potentially represents a useful tool for risk stratification in the primary and secondary prevention setting. However, there are still unresolved methodological issues regarding the measurement of lipoprotein a levels. Targeting lipoprotein a in order to reduce vascular risk is hampered by the lack of well tolerated and effective pharmacological interventions. Moreover, it has not yet been established whether such a reduction will result in fewer vascular events. The risk attributed to lipoprotein a may be reduced by aggressively tackling other vascular risk factors, such as low-density lipoprotein cholesterol.

DOI10.1097/HCO.0b013e32832ac21a
Alternate JournalCurr. Opin. Cardiol.
PubMed ID19417640

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.